HRGN.US Harvard Apparatus Regenerative Technology Inc.
- Market cap
- USD 40.2M
- P/E
- -
- P/B
- 267.53x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is HRGN.US undervalued?
Graham numberThe Graham number of Harvard Apparatus Regenerative Technology Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Harvard Apparatus Regenerative Technology Inc. fundamental analysis
No fundamental analysis for Harvard Apparatus Regenerative Technology Inc. yet.
Harvard Apparatus Regenerative Technology Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Harvard Apparatus Regenerative Technology Inc.
Harvard Apparatus Regenerative Technology Inc., a clinical-stage biotechnology company, focuses on developing regenerative-medicine treatments for disorders of the gastro-intestinal system and other organs resulting from cancer, trauma, or birth defects. The company's lead product candidate is Cellspan Esophageal Implant for the treatment of severe esophageal disease. It's pipeline includes organ-regeneration technology for the repair or replacement of diseased or damaged or…
Full company profileHarvard Apparatus Regenerative Technology Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Harvard Apparatus Regenerative Technology Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 103K | 430K | 704K | 1.28M |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 79.0K | 160K | 58.0K | 86.0K |
| Operating Income | -8.40M | -4.88M | -8.47M | -6.15M | -8.99M | -7.73M | -6.92M | -6.60M |
| EBITDA | -8.09M | -4.69M | - | -5.99M | -8.80M | -7.53M | -6.76M | -6.46M |
| Net Income | -8.33M | -4.87M | -7.98M | -6.07M | -8.95M | -7.73M | -6.87M | -6.59M |
| EPS | -1.02 | -0.52 | -0.74 | -0.50 | -0.64 | -0.49 | -0.39 | -0.37 |
| Balance Sheet | ||||||||
| Total Assets | 1.99M | 2.08M | 1.87M | 2.40M | 2.61M | 4.44M | 2.68M | 1.69M |
| Total Liabilities | 903K | 951K | 4.90M | 1.41M | 968K | 1.22M | 1.62M | 3.06M |
| Shareholders' Equity | 1.09M | 1.13M | -3.03M | 989K | 1.65M | 3.22M | 1.06M | -1.38M |
| Cash & Short-term Investments | 913K | 1.03M | 1.24M | 1.24M | 432K | 2.49M | 1.35M | 351K |
| Cash Flow | ||||||||
| Operating Cash Flow | -6.06M | -4.04M | -2.63M | -5.11M | -6.94M | -4.85M | -3.83M | -3.01M |
| Capital Expenditure | 129K | 7.00K | 0.00 | 5.00K | 11.0K | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | -6.19M | -4.05M | -2.63M | -5.11M | -6.95M | -4.85M | -3.83M | -3.01M |
| Ratios | ||||||||
| ROE | -765.1% | -432.4% | - | -614.1% | -543.4% | -240.0% | -649.9% | - |
| ROA | -418.3% | -234.3% | -427.5% | -253.0% | -342.2% | -174.1% | -256.6% | -391.2% |
| Net Profit Margin | - | - | - | - | -8,684.5% | -1,798.1% | -975.7% | -515.0% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Harvard Apparatus Regenerative Technology Inc. dividends
Harvard Apparatus Regenerative Technology Inc. has not paid dividends in the last 7 fiscal years.
Last stock split: 1:20 on Dec 22, 2017.
Who owns Harvard Apparatus Regenerative Technology Inc.
- Insiders 49.32%
- Institutions 0.00%
- Public & others 50.68%
- Shares outstanding 20.3M
- Free float 8.91M
Harvard Apparatus Regenerative Technology Inc. company profile
- Company name
- Harvard Apparatus Regenerative Technology Inc.
- Ticker
- HRGN.US
- Exchange
- USA Stocks
- Sector
- Consumer Defensive
- Industry
- Biotechnology
- Employees
- 8
- Fiscal year end
- December
- Address
- 84 October Hill Road, Holliston, MA, United States, 01746
- Phone
- 774 233 7300
- Website
- hregen.com
About Harvard Apparatus Regenerative Technology Inc.
Harvard Apparatus Regenerative Technology Inc., a clinical-stage biotechnology company, focuses on developing regenerative-medicine treatments for disorders of the gastro-intestinal system and other organs resulting from cancer, trauma, or birth defects. The company's lead product candidate is Cellspan Esophageal Implant for the treatment of severe esophageal disease. It's pipeline includes organ-regeneration technology for the repair or replacement of diseased or damaged organs; and product candidates to treat conditions of the esophagus, including traumatic injury, caustic burns, tissue damage following chemoradiation therapy, birth defects, and reconstruction of the colon and uterus wound repair. The company also sells consumer health products that focuses on personal healthcare, including dietary supplements. Harvard Apparatus Regenerative Technology Inc. was formerly known as Biostage, Inc. and changed its name to Harvard Apparatus Regenerative Technology Inc. in July 2023. The company was founded in 2009 and is headquartered in Holliston, Massachusetts.
Harvard Apparatus Regenerative Technology Inc. management
5- Mr. Junli He C.F.A.CEO & Chairman · born 1974
- Mr. Yu Hong B.S., C.F.A., M.S.President · born 1973
- Mr. Joseph L. Damasio Jr.Chief Financial Officer · born 1974
- Dr. William L. Fodor Ph.D.Chief Scientific Officer · born 1959
- Dr. Shunfu Hu Ph.D.Corporate Secretary